blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3340987

EP3340987 - COMBINATION OF RIBOCICLIB AND DABRAFENIB FOR TREATING OR PREVENTING B-RAF MUTANT COLORECTAL CANCER [Right-click to bookmark this link]
Former [2018/27]COMBINATION OF RIBOCICLIB AND DABRAFENIB FOR TREATING OR PREVENTING CANCER
[2022/12]
StatusThe application is deemed to be withdrawn
Status updated on  16.12.2022
Database last updated on 08.04.2026
FormerGrant of patent is intended
Status updated on  15.03.2022
FormerExamination is in progress
Status updated on  06.04.2020
FormerRequest for examination was made
Status updated on  01.06.2018
FormerThe international publication has been made
Status updated on  11.03.2017
Formerunknown
Status updated on  11.11.2016
Most recent event   Tooltip16.12.2022Application deemed to be withdrawnpublished on 18.01.2023  [2023/03]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2018/27]
Inventor(s)01 / CAPONIGRO, Giordano
c/o Novartis Institutes for
BioMedical Research Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139 / US
02 / HORN-SPIROHN, Thomas
c/o Novartis Institutes for
BioMedical Research Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139 / US
03 / LEHAR, Joseph
c/o Novartis Institutes for
BioMedical Research Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139 / US
 [2018/27]
Representative(s)Rudge, Sewkian
Novartis AG
Patent Department
Lichtstrasse 35
4056 Basel / CH
[2018/27]
Application number, filing date16763589.525.08.2016
[2018/27]
WO2016IB55076
Priority number, dateUS201562211027P28.08.2015         Original published format: US 201562211027 P
[2018/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017037587
Date:09.03.2017
Language:EN
[2017/10]
Type: A1 Application with search report 
No.:EP3340987
Date:04.07.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 09.03.2017 takes the place of the publication of the European patent application.
[2018/27]
Search report(s)International search report - published on:EP09.03.2017
ClassificationIPC:A61K31/4439, A61K31/506, A61K31/519, A61P35/00, A61P35/02
[2022/12]
CPC:
A61K31/519 (EP,US); A61K31/4439 (EP,US); A61K31/506 (EP,US);
A61P35/02 (EP,US); A61K2300/00 (US)
C-Set:
A61K31/4439, A61K2300/00 (US,EP);
A61K31/506, A61K2300/00 (US,EP);
A61K31/519, A61K2300/00 (EP,US)
Former IPC [2018/27]A61K31/4439, A61K31/506, A61K31/519, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/27]
TitleGerman:KOMBINATION VON RIBOCICLIB UND DABRAFENIB ZUR VORBEUGUNG ODER BEHANDLUNG VON B-RAF MUTIERTEM KOLORECTALEN KREBS[2022/12]
English:COMBINATION OF RIBOCICLIB AND DABRAFENIB FOR TREATING OR PREVENTING B-RAF MUTANT COLORECTAL CANCER[2022/12]
French:COMBINAISON DE RIBOCICLID ET DE DABRAFENIB POUR LE TRAITEMENT OU LA PRÉVENTION DU CANCER COLORECTAL B-RAF MUTÉ[2022/12]
Former [2018/27]KOMBINATION VON RIBOCICLIB UND DABRAFENIB ZUR VORBEUGUNG ODER BEHANDLUNG VON KREBS
Former [2018/27]COMBINATION OF RIBOCICLIB AND DABRAFENIB FOR TREATING OR PREVENTING CANCER
Former [2018/27]COMBINAISON DE RIBOCICLID ET DE DABRAFENIB POUR LE TRAITEMENT OU LA PRÉVENTION DU CANCER
Entry into regional phase28.03.2018National basic fee paid 
28.03.2018Designation fee(s) paid 
28.03.2018Examination fee paid 
Examination procedure28.02.2018Amendment by applicant (claims and/or description)
28.02.2018Date on which the examining division has become responsible
28.03.2018Examination requested  [2018/27]
09.04.2020Despatch of a communication from the examining division (Time limit: M06)
21.12.2020Reply to a communication from the examining division
16.03.2022Communication of intention to grant the patent
27.07.2022Application deemed to be withdrawn, date of legal effect  [2023/03]
01.09.2022Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2023/03]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
21.12.2020Request for further processing filed
21.12.2020Full payment received (date of receipt of payment)
Request granted
21.01.2021Decision despatched
Fees paidRenewal fee
10.08.2018Renewal fee patent year 03
15.08.2019Renewal fee patent year 04
13.08.2020Renewal fee patent year 05
13.08.2021Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.08.202207   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]   KURT SAMSON: "LEE011 CDK Inhibitor Showing Early Promise in Drug-Resistant Cancers", ONCOLOGY TIMES, vol. 36, no. 3, 1 February 2014 (2014-02-01), pages 39 - 40, XP055317020, ISSN: 0276-2234, DOI: 10.1097/01.COT.0000444043.33304.c1

DOI:   http://dx.doi.org/10.1097/01.COT.0000444043.33304.c1
 [Y]   A.C. WOOD ET AL: "Abstract 1000: Combination CDK4/6 and ALK inhibition demonstrates on-target synergy against neuroblastoma", CANCER RESEARCH - PROCEEDINGS AACR ANNUAL MEETING 2014; APRIL 5-9 2014, SAN DIEGO, CA, 1 October 2014 (2014-10-01), XP055317513, Retrieved from the Internet [retrieved on 20161108]

DOI:   http://dx.doi.org/10.1158/1538-7445.AM2014-1000
 [Y]   JEFFREY A SOSMAN ET AL: "A Phase 1b/2 Study of LEE011 in Combination With Binimetinib (MEK162) in Patients With Advanced NRAS-Mutant Melanoma: Early Encouraging Clinical Activity", 1 January 2014 (2014-01-01), XP055311605, Retrieved from the Internet [retrieved on 20161018]
 [Y]   FLAHERTY KEITH T ET AL: "Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations", vol. 367, no. 18, 1 November 2012 (2012-11-01), pages 1694 - 1703, XP002725869, ISSN: 0028-4793, Retrieved from the Internet [retrieved on 20120929], DOI: 10.1056/NEJMOA1210093

DOI:   http://dx.doi.org/10.1056/NEJMoa1210093
 [Y]   ALEXANDER M. MENZIES ET AL: "Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond", EUROPEAN JOURNAL OF CANCER, vol. 49, no. 15, 1 October 2013 (2013-10-01), pages 3229 - 3241, XP055203734, ISSN: 0959-8049, DOI: 10.1016/j.ejca.2013.06.027

DOI:   http://dx.doi.org/10.1016/j.ejca.2013.06.027
by applicantWO2010020675
 WO2009137391
 WO2010029082
   FISCHER, P. M., CURR. OPIN. DRUG DISCOVERY DEV., vol. 4, 2001, pages 623 - 634
   DAVIES, H. ET AL., NATURE, vol. 9, 2002, pages 1 - 6
   GARNETT, M.J.; MARAIS, R., CANCER CELL, vol. 6, 2004, pages 313 - 319
   ZEBISCH, A.; TROPPMAIR, J., CELL. MOL. LIFE SCI., vol. 63, 2006, pages 1314 - 1330
   MIDGLEY, R.S.; KERR, D.J., CRIT. REV. ONE HEMATOL., vol. 44, 2002, pages 109 - 120
   SMITH, R.A. ET AL., CURRO TOP. MED. CHEM., vol. 6, 2006, pages 1071 - 1089
   DOWNWARD, J., NAT. REV. CANCER, vol. 3, 2003, pages 11 - 22
   COHEN ET AL., J. NAT. CANCER INST., vol. 95, no. 8, 2003, pages 625 - 627
   KIMURA ET AL., CANCER RES., vol. 63, no. 7, 2003, pages 1454 - 1457
   GARNETT ET AL., CANCER CELL, vol. 6, 2004, pages 313 - 319
   SOMMERER ET AL., ONCOGENE, vol. 23, no. 2, 2004, pages 554 - 558
   ZEBISCH ET AL., CELL. MOL. LIFE SCI., vol. 63, 2006, pages 1314 - 1330
   MORENO-BUENO ET AL., CLIN. CANCER RES., vol. 12, no. 12, 2006, pages 3865 - 3866
   TANNAPFEL ET AL., GUT, vol. 52, no. 5, 2003, pages 706 - 712
   KNOBBE ET AL., ACTA NEUROPATHOL. (BERL., vol. 108, no. 6, 2004, pages 467 - 470
   GARNETT ET AL., CANCER CELL, 2004
   YUEN ET AL., CANCER RES., vol. 62, no. 22, 2002, pages 6451 - 6455
   ZEBISCH ET AL., CELL. MOL. LIFE SCI., 2006
   LEE ET AL., ONCOGENE, vol. 22, no. 44, 2003, pages 6942 - 6945
   WEBER ET AL., ONCOGENE, vol. 22, no. 30, 2003, pages 4757 - 4759
   GUSTAFSSON ET AL., LEUKEMIA, vol. 19, no. 2, 2005, pages 310 - 312
   LEE ET AL., LEUKEMIA, vol. 18, no. 1, 2004, pages 170 - 172
   CHRISTIANSEN ET AL., LEUKEMIA, vol. 19, no. 12, 2005, pages 2232 - 2240
   MIZUCHI ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 326, no. 3, 2005, pages 645 - 651
   FIGL ET AL., ARCH. DERMATOL., vol. 143, no. 4, 2007, pages 495 - 499
   LEE ET AL., BR. J. CANCER, vol. 89, no. 10, 2003, pages 1958 - 1960
   EYCHENE ET AL., ONCOGENE, vol. 10, no. 6, 1995, pages 1159 - 1165
   NG ET AL., BR. J. HAEMATOL, vol. 123, no. 4, 2003, pages 637 - 645
   BROSE ET AL., CANCER RES., vol. 62, no. 23, 2002, pages 6997 - 7000
   COHEN ET AL., J. NAT. CANCER INST., 2003
   PARDO ET AL., EMBO J., vol. 25, no. 13, 2006, pages 3078 - 3088
   RUSSELL; MCCLUGGAGE, J. PATHOL., vol. 203, no. 2, 2004, pages 617 - 619
   MORENO-BUENO ET AL., CLIN. CANCER RES., 2006
   ISHIMURA ET AL., CANCER LETT., vol. 199, no. 2, 2003, pages 169 - 173
   DE MARTINO ET AL., J. ENDOCRINOL. INVEST., vol. 30, no. 1, 2007, pages RC1 - 3
   CHO ET AL., INT. J. CANCER, vol. 119, no. 8, 2006, pages 1858 - 1862
   NAGY ET AL., INT. J. CANCER, vol. 106, no. 6, 2003, pages 980 - 981
   RODRIGUEZ-VICIANA ET AL., SCIENCE, vol. 311, no. 5765, 2006, pages 1287 - 1290
   ZEBISCH ET AL., CANCER RES., vol. 66, no. 7, 2006, pages 3401 - 3408
   ZEBISCH, CELL. MOL. LIFE SCI., 2006
   VANHAESEBROECK ET AL., ANNU. REV. BIOCHEM, vol. 70, 2001, pages 535
   KATSO ET AL., ANNU. REV. CELL DEV. BIOL., vol. 17, 2001, pages 615
   FRUMAN ET AL., ANNU REV. BIOCHEM., vol. 67, 1998, pages 481
   SUIRE ET AL., CURRO BIOL., vol. 15, 2005, pages 566
   STEPHENS ET AL., CELL, vol. 89, 1997, pages 105
   KATSO ET AL., ANNU. REV. CELL DEV. BIOL., vol. 17, 2001, pages 615 - 675
   CANTLEY ET AL., CELL, vol. 64, pages 281
   ESCOBEDO; WILLIAMS, NATURE, vol. 335, 1988, pages 85
   FANTL ET AL., CELL, vol. 69, 1992, pages 413
   FANTL ET AL., CELL, vol. 69, 1992, pages 413 - 423
   BADER ET AL., NATURE REV. CANCER, vol. 5, 2005, pages 921
   VIVANCO; SAWYER, NATURE REV. CANCER, vol. 2, 2002, pages 489
   KANG, PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 802
   SAMUELS ET AL., SCIENCE, vol. 304, 2004, pages 554
   SAMUELS ET AL., CANCER CELL, vol. 7, 2005, pages 561 - 573
   PARSONS ET AL., NATURE, vol. 436, 2005, pages 792
   HENNESSEY, NATURE REV. DRUG DISC., vol. 4, 2005, pages 988 - 1004
   KING A. J. ET AL., CANCER RES., vol. 66, 2006, pages 11100 - 11105
   "The Handbook of Pharmaceutical Excipients", 2003, AMERICAN PHARMACEUTICALS ASSOCIATION
   "Remington: the Science and Practice of Pharmacy", 2003, LIPPINCOTT WILLIAMS & WILKINS
   "Remington's Pharmaceutical Sciences", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329
   HOLFORD, N. H. G.; SCHEINER, L. B., CLIN. PHARMACOKINET., vol. 6, 1981, pages 429 - 453
   LOEWE, S.; MUISCHNEK, H., ARCH. EXP. PATHOL PHARMACOL., vol. 114, 1926, pages 313 - 326
   CHOU, T. C.; TALALAY, P., ADV. ENZYME REGUL, vol. 22, 1984, pages 27 - 55
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.